Evidence map›Paper›PMID 34833048›Full record

ArticleLife (Basel, Switzerland)2021

The Urine Biomarker PUR-4 Is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers.

Richard Y Ball, Ryan Cardenas, Mark S Winterbone, Marcelino Y Hanna, Chris Parker, Rachel Hurst, Daniel S Brewer, Lauren D'Sa, Rob Mills, Colin S Cooper and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Richard Y BallNorfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK.ORCID 0000-0003-0579-3911
Ryan CardenasNorwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
Mark S WinterboneNorwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
Marcelino Y HannaUrology Department Castle Hill, Hull University Teaching Hospital, Castle Rd, Cottingham HU16 5JQ, UK.
Chris ParkerInstitute of Cancer Research, Sutton SM2 5NG, UK.
Rachel HurstNorwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
Daniel S BrewerNorwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.ORCID 0000-0003-4753-9794
Lauren D'SaNorfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK.
Rob MillsNorfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK.
Colin S CooperNorwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
Jeremy ClarkNorwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
University of East Anglia · GBNorfolk and Norwich University Hospitals NHS Foundation Trust · GBCastle Hill Hospital · GBInstitute of Cancer Research · GB

Funding

Movember Foundation RIA18-ST2-014Prostate Cancer UK RIA18-ST2-014
6 · The paper itself

Abstract

The Prostate Urine Risk (PUR) biomarker is a four-group classifier for predicting outcome in patients prior to biopsy and for men on active surveillance. The four categories correspond to the probabilities of the presence of normal tissue (PUR-1), D'Amico low-risk (PUR-2), intermediate-risk (PUR-3), and high-risk (PUR-4) prostate cancer. In the current study we investigate how the PUR-4 status is linked to Gleason grade, prostate volume, and tumor volume as assessed from biopsy (

Indexed as

cancerGleason pattern 4prostatePURPUR-4urine

Identifiers

PMID34833048
PMCPMC8622091
OpenAlexW3210240866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.